KR100338521B1 - Plant extract for eating activating macrophage - Google Patents
Plant extract for eating activating macrophage Download PDFInfo
- Publication number
- KR100338521B1 KR100338521B1 KR1019990013398A KR19990013398A KR100338521B1 KR 100338521 B1 KR100338521 B1 KR 100338521B1 KR 1019990013398 A KR1019990013398 A KR 1019990013398A KR 19990013398 A KR19990013398 A KR 19990013398A KR 100338521 B1 KR100338521 B1 KR 100338521B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- macrophage
- edible plant
- extraction
- mol
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 101
- 239000000419 plant extract Substances 0.000 title claims abstract description 28
- 230000003213 activating effect Effects 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 99
- 235000018927 edible plant Nutrition 0.000 claims abstract description 45
- 238000000605 extraction Methods 0.000 claims abstract description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000005338 Allium tuberosum Nutrition 0.000 claims abstract description 30
- 235000000346 sugar Nutrition 0.000 claims abstract description 27
- 230000004913 activation Effects 0.000 claims description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000001641 gel filtration chromatography Methods 0.000 claims description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 240000008654 Allium ramosum Species 0.000 claims 3
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 244000003377 Allium tuberosum Species 0.000 abstract description 27
- 239000012190 activator Substances 0.000 abstract description 17
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 240000005893 Pteridium aquilinum Species 0.000 abstract description 3
- 235000009936 Pteridium aquilinum Nutrition 0.000 abstract description 3
- 238000000638 solvent extraction Methods 0.000 abstract description 3
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000000126 substance Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000985694 Polypodiopsida Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000035781 nonspecific defense system Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 대식세포 활성화능을 갖는 식용식물 추출물에 관한 것으로써, 더욱 상세하게는 봉출(학명:Curcuma zedoaria), 중국부추(학명:Allium tuberosum L.) 및 고사리(학명:Pteridium aquilinum) 중에서 선택된 식용식물을 용매추출 및 알코올추출하여 얻은 천연 추출물로써, 인체에 무해하며, 특히 종래의 대식세포 활성화제로 많이 이용되는 당지방질에 비하여 대식세포 활성화능이 월등하게 우수하여 대식세포 활성화제로 유용한 대식세포 활성화능을 갖는 식용식물 추출물에 관한 것이다.The present invention relates to an edible plant extract having a macrophage activating ability, and more specifically, edible selected from the extract ( Curcuma zedoaria ), Chinese leek ( Chem : Allium tuberosum L. ) and fern (C : Pteridium aquilinum ) As a natural extract obtained by solvent extraction and alcohol extraction of plants, it is harmless to the human body. Especially, the macrophage activating ability is superior to the sugar fat which is widely used as a conventional macrophage activator. It relates to an edible plant extract having.
Description
본 발명은 대식세포 활성화능을 갖는 식용식물 추출물에 관한 것으로써, 더욱 상세하게는 봉출(학명:Curcuma zedoaria), 중국부추(학명:Allium tuberosum L.) 및 고사리(학명:Pteridium aquilinum) 중에서 선택된 식용식물을 용매추출 및 알코올추출하여 얻은 천연 추출물로써, 인체에 무해하며, 특히 종래의 대식세포 활성화제로 많이 이용되는 당지방질에 비하여 대식세포 활성화능이 월등하게 우수하여 대식세포 활성화제로 유용한 대식세포 활성화능을 갖는 식용식물 추출물에 관한 것이다.The present invention relates to an edible plant extract having a macrophage activating ability, and more specifically, edible selected from the extract ( Curcuma zedoaria ), Chinese leek ( Chem : Allium tuberosum L. ) and fern (C : Pteridium aquilinum ) As a natural extract obtained by solvent extraction and alcohol extraction of plants, it is harmless to the human body. Especially, the macrophage activating ability is superior to the sugar fat which is widely used as a conventional macrophage activator. It relates to an edible plant extract having.
암의 퇴치와 예방이 21세기를 목전에 둔 생명 과학이 해결해야 할 커다란 과제 중 하나임은 재언할 필요가 없다. 지금까지는 암의 치료방법으로 외과적 수술요법, 방사선요법 뿐만 아니라, 항암성 화학요법제를 투여하는 방법이 많이 사용되어 왔다. 그러나, 기존의 화학요법제는 정상 세포에 대하여 독성 및 부작용을 나타낼 뿐만 아니라, 이런 화학요법제에 대하여 암세포가 내성을 가지는 문제점이 제시되고 있다. 따라서, 암세포에만 선택적으로 작용하고, 독성이 적으면서도 우수한 항암제를 개발하려는 연구가 끊임없이 시도되고 있다.There is no need to reiterate that combating and preventing cancer is one of the great challenges that life sciences face in the 21st century. Until now, as a method of treating cancer, there have been many methods of administering chemotherapy as well as surgical surgery and radiotherapy. However, the existing chemotherapeutic agents not only show toxicity and side effects for normal cells, but also have been proposed to cause cancer cells tolerate such chemotherapeutic agents. Therefore, studies have been continuously made to develop anticancer agents that selectively act only on cancer cells and have low toxicity.
면역학이 발전함에 따라, 여러 가지 면역 기능 물질들이 생체의 면역 부전 상태를 개선 또는 치료하는 면역요법제로 개발되어 암의 치료에 사용되고 있다. 이들 면역요법제의 기원은 고등식물을 위시하여 세균류, 진균류, 인체 등 다양하다. 그러나 면역요법제의 일부는 임상투여시 생체내 심한 부작용을 나타내기도 한다.With the development of immunology, various immune functional substances have been developed as immunotherapeutic agents for improving or treating the immune dysfunction state of a living body and are used for the treatment of cancer. The origin of these immunotherapeutics is various, including higher plants, such as bacteria, fungi, and the human body. However, some immunotherapeutic agents have severe side effects in vivo upon clinical administration.
근래에는 암에 대한 생체 면역계의 반응에 관하여 더욱 진전된 이행과 폭넓은 분석으로 종양에 대한 숙주의 방어 방식을 여러 가지 기전으로 설명할 수 있게 되었다. 종양 세포에 직접 작용하여 성장 억제 또는 사멸을 초래하는 기전, 생체의 면역 반응을 강화시키는 기전, 방어체계를 활성화하는 중개자에 작용하여 숙주의 암에 대한 방어능력을 증가시키는 기전 또는 종양 세포의 숙주 면역 체계에 대한 감수성을 높여 숙주의 항종양 효과를 증가시키는 기전 등이 제시되고 있다. 또한, 미분화된 종양세포를 촉진시켜 분열하지 않은 성숙된 세포로 만드는 기전, 종양에 대한 화학요법 또는 방사선요법에 따르는 생체의 세포 독성에 대한 피해를 경감시킴으로써 종양 치료효과를 증가시키는 기전 등이 발표되었다. 이러한 기전을 나타내는 물질들을 생체 반응 조절물질이라 하며, 이들은 합성된 화학요법제와는 달리 생체의 생물학적 반응에 영향을 미쳐 암에 대한 억제 효과를 나타냄으로써 치료시 부작용을 줄일 수 있으며 또한 그 효과도 증대시킬 수 있다.In recent years, more advanced implementations and extensive analysis of the response of the biological immune system to cancer have led to several mechanisms that explain the host's defenses against tumors. Mechanisms that directly act on tumor cells, resulting in growth inhibition or death, mechanisms that enhance the immune response of a living body, mechanisms that act on a mediator that activates the defense system or increase host cancer's ability to defend against cancer or host immunity to tumor cells The mechanism of increasing the sensitivity to the system to increase the antitumor effect of the host has been proposed. In addition, mechanisms for promoting undifferentiated tumor cells into undivided mature cells, and increasing the effect of tumor treatment by reducing the damage to the cytotoxicity of living organisms following chemotherapy or radiation therapy for tumors have been published. . Substances that exhibit these mechanisms are called bioresponders, and unlike synthetic chemotherapeutic agents, they can affect biological responses of the body and thus have an inhibitory effect on cancer, thereby reducing side effects and increasing effects. You can.
면역계 증강소재인 대식세포 활성화제는 현재까지 연구 개발되어 온 식·의약품소재들 중에서 암 뿐만 아니라, 각종 새로운 질병 및 난치병의 치료와 관련하여 차세대의 식·의약품 신소재로 분류되고 있다. 면역계는 크게 선천적 면역계와 후천적 면역계로 나뉘어 지는데 선천적 면역계는 대식세포에 의한 포식작용, 보체작용의 부경로, 그리고 피부와 상피에 의해 주도되는 면역반응이다.Macrophage activator, an immune system enhancement material, is classified as a next generation food and drug new material in the treatment of various new diseases and incurable diseases as well as cancer among food and drug materials that have been researched and developed up to now. The immune system is largely divided into the innate immune system and the acquired immune system. The innate immune system is a macrophage phagocytosis, complementary pathway, and an immune response driven by the skin and epithelium.
후천적 면역계는 선천적 면역계를 통과한 병원체에 대한 면역 반응으로 다시 체액성 면역계와 세포성 면역계로 나눌 수 있고 체액성 면역계는 B 임파구에서 생산되는 항체에 대한 혈액 내 반응이며, 세포성 면역계는 세포독성의 T 세포와 T 세포 조절자(helper T Cell)에 대식세포가 항원을 제시하면서 일어나는 생체 내 조직에서의 면역 반응이다.The acquired immune system is an immune response to pathogens that have passed the innate immune system, which can be divided into humoral and cellular immune systems. Humoral immune systems are blood responses to antibodies produced in B lymphocytes. It is an immune response in tissue in vivo that occurs when a macrophage presents antigens to T cells and T cell helpers.
이와 같이, 대식세포는 선천적 또는 후천적 면역계의 두 반응 모두에 관여하는 면역 세포로 항미생물 작용, 항암 작용, 그리고 조직 손상의 효과기 기능(effector function)을 가지는 것으로 알려져 있다.As such, macrophages are immune cells involved in both responses of the innate or acquired immune system and are known to have effector functions of antimicrobial, anticancer, and tissue damage.
자연계에 수없이 존재하는 천연물질 중에서 생체에 대한 기능이 다양한 물질들이 존재할 것으로 기대되어 이에 대한 관심이 날로 증가하고 있으며, 특히 식품재료, 생약(한방제재) 및 균류로부터 면역활성이 존재하는 물질을 얻으려는 노력이 계속되고 있다. 특히 생약제재들은 면역계, 내분비계, 순환계 등에 중요한 영향을 미치고 있음이 알려져 있으며, 특정 한약재의 경우 만성 감염, 류마티스 관절염(rheumatoid arthritis), 네프로시스(nephrosis) 등과 같은 자기 면역 질환(autoimmune disease)에 대해서도 임상적으로 그 효과가 인정되고 있다. 이들은 주로 저분자 획분보다는 고분자 획분에서 그 활성을 나타내는데 특히 이들 생약 유래의 고분자 물질 중에는 인터페론 유도 활성, 분열촉진 활성, 항보체(anti-complementary) 활성, 항종양 활성, 항염증 활성, 임파구 분열촉진 활성 및 식작용 증강활성 등의 면역조절 활성이 발견되고 있으며, 이들 활성의 일부에 대해서는 활성성분이 다당임이 밝혀져 주목되고 있다.Among the natural substances that exist in the natural world, various substances with various functions for living organisms are expected to increase in interest, and in particular, the substances with immune activity from food ingredients, herbal medicines and fungi are obtained. Efforts are ongoing. In particular, herbal medicines are known to have an important effect on the immune system, the endocrine system, the circulatory system, and certain herbal medicines are also used for autoimmune diseases such as chronic infection, rheumatoid arthritis, and nephrosis. The effect is clinically recognized. They are mainly active in polymer fractions rather than in low molecular fractions. Especially among these herbal-derived polymeric substances, interferon-inducing activity, fission promoting activity, anti-complementary activity, anti-tumor activity, anti-inflammatory activity, lymphocyte proliferation activity and Immunomodulatory activities such as phagocytosis enhancing activity have been found, and for some of these activities, it has been found that the active ingredient is polysaccharide.
천연물로부터 보고되는 대식세포 활성화 성분으로 식물기원성 다당류들이 대부분인데 특히 이들 다당류들은 항암 활성 및 항보체 활성을 동시에 나타내기도 하며 항바이러스 작용, 렉티큘로엔도테리알 활성(recticuloendothelial activation), 항염증 활성, 저혈당 활성을 나타내기도 한다. 실제로 표고버섯의 렌티난(lentinan)과 같은 다당류는 항암효과, 항체활성과 대식세포 활성 등에 대하여 보고되어 있으며, 도꼬마리 추출물의 면역억제 작용, 당귀추출물의 면역계 증강에 의한 B 임파구 증식효과 등의 면역증강 주성분이 단백결합다당이거나 다당류로 알려져 있다. 최근 들어 수종의 식물유래 다당들의 항종양효과에 관하여도 알려지고 있는데 이들의 기질은 현재 암세포에 직접적으로 세포독성을 나타내기보다는 종양에 대한 숙주의 방어력 즉, 면역계의 증강에 의한 결과로 이해되고 있다. 특히 숙주 비특이적 방어계의 중요한 역할을 담당하는 대식세포가 이들 다당에 의하여 자극을 받아 활성화되고 그 결과 퍼짐(spreading), 탐식작용, 음세포작용을 통한 항균, 항종양 작용의 증가와 암세포에 직접적인 손상을 줄 뿐만 아니라 다당의 보체계의 활성화에 따른 옵소닌 작용, 화학자극운동을 일으켜 암세포를 공격하는 것으로 알려지고 있다.Most of the plant-derived polysaccharides are macrophage-activating components reported from natural products. Especially, these polysaccharides exhibit both anti-cancer activity and anti-complementary activity, and also have antiviral activity, recticuloendothelial activation, and anti-inflammatory activity. It also has hypoglycemic activity. In fact, polysaccharides such as lentinan from shiitake mushrooms have been reported for their anticancer effects, antibody activity and macrophage activity. The main component is known as protein-linked polysaccharide or polysaccharide. Recently, antitumor effects of several plant-derived polysaccharides have been known, and their substrates are now understood as a result of the host's defense against tumors, i.e., the enhancement of the immune system, rather than direct cytotoxicity to cancer cells. . In particular, macrophages, which play an important role in the host's nonspecific defense system, are stimulated and activated by these polysaccharides, resulting in spreading, phagocytosis, antimicrobial activity through negative cell action, increased antitumor activity and direct damage to cancer cells. It is known to attack cancer cells by giving opsonin action and chemical stimulation movement following activation of polysaccharide complement system.
따라서, 식용식물로부터 대식세포 활성화도가 높은 물질을 추출함으로써, 인체에 무해하고, 기존의 대식세포 활성화제보다 활성화도가 우수한 대식세포 활성화제에 대한 면역기능 조절물질이 요구된다.Therefore, by extracting a substance having a high degree of macrophage activation from the edible plant, there is a need for a substance that modulates immune function against a macrophage activator that is harmless to the human body and has superior activation than existing macrophage activators.
본 발명은 인체에 대한 부작용이 없는 대식세포 활성화제용 추출물을 제조하기 위해 여러 가지 식용식물의 대식세포 활성화도를 검토한 결과, 봉출 등의 식용식물로부터 특정의 추출조건으로 용매추출 및 알코올 추출하여 얻은 분획을 통하여 대식세포 활성화능이 우수한 추출물과 그 추출방법을 제공하는데 그 목적이 있다.The present invention is to examine the degree of macrophage activation of various edible plants in order to prepare an extract for macrophage activator without side effects on the human body, obtained by solvent extraction and alcohol extraction from the edible plants, such as the extract under specific extraction conditions It is an object of the present invention to provide an extract and a method of extracting the superior macrophage activation ability through fractions.
또한, 봉출로부터 분리한 대식세포 활성화능이 우수한 정제분 및 정제분의 분리 방법을 제공하는데 그 목적이 있다.In addition, an object of the present invention is to provide a purified powder having excellent macrophage activating ability separated from the extract and a method for separating purified powder.
도 1은 식용식물의 계통 추출 과정을 나타낸다.Figure 1 shows the process of extracting the edible plant.
본 발명은 식용식물인 봉출을 용매추출한 후, 이를 다시 알코올 추출하는 것을 특징으로 하는 대식세포 활성화능을 갖는 식용식물 추출물을 그 특징으로 한다.The present invention is characterized in that the edible plant extract having a macrophage activating ability, characterized in that the extraction of the solvent edible plant, and then extract the alcohol again.
또한, 본 발명은 식용식물 추출물을 제조함에 있어서, 봉출, 중국부추 및 고사리 중에서 선택된 식용식물을 1 ∼ 8 시간 동안 추출 용매로 수회 추출하고, 이를 다시 알코올로 추출하여 침전 분획물을 얻는, 대식세포 활성화능을 갖는 식용식물 추출물의 제조방법을 그 특징으로 한다.In addition, the present invention in the preparation of the edible plant extract, extract the edible plant selected from the extract, Chinese leek and fern several times with an extraction solvent for 1 to 8 hours, and then extracted with alcohol again to obtain a precipitate fraction, macrophage activation It is characterized by a method for producing an edible plant extract having the ability.
또한, 본 발명은 상기 방법에 따라 제조한 봉출 추출물을 이온교환 크로마토그래피, 소수 상호작용 크로마토그래피 및 겔 여과 크로마토그래피 방법으로 분획하여 대식세포 활성화능을 갖는 순수한 정제분을 제조하는 방법을 포함한다.In addition, the present invention comprises a method for producing a pure purified powder having a macrophage activation ability by fractionating the extract extract prepared according to the above method by ion exchange chromatography, hydrophobic interaction chromatography and gel filtration chromatography.
본 발명에 따른 대식세포 활성화능이 우수한, 봉출을 포함하는 식용식물 추출물은 종래의 대식세포 활성화제보다 대식세포 활성화도가 우수한 것으로써, 특히 천연식물에서 용이하게 얻을 수 있다는데 그 특징을 두고 있다.The edible plant extract, including the sequestration, having excellent macrophage activating ability according to the present invention is superior in macrophage activation than conventional macrophage activators, and is characterized in that it can be easily obtained from natural plants.
오래전부터 식용으로 이용되고 있는 전통양념채소류, 서양 향신료, 건강채소류를 계통 추출하여 대식세포 활성화도를 비교한 결과, 봉출을 비롯한 중국부추, 고사리 등의 식용식물의 추출물이 종래의 대식세포 활성화제보다 대식세포 활성화도가 우수하였으며, 특히 봉출 추출물의 대식세포 활성화도가 우수한 것을 확인하였다.Extraction of edible plants such as Chinese leek, fern, etc., compared to conventional macrophage activators, by extracting traditional seasoned vegetables, western spices, and health vegetables, which were used for a long time Macrophage activation was excellent, in particular it was confirmed that the macrophage activation of the extract extract.
본 발명에서 사용된 봉출은 울금과의 동속약초로써 생약제재로 전통 한방에서 널리 사용하여 왔고 동남아의 식품향신재의 주요성분인 쿠르쿠민을 포함하고 있으며 항산화 효과, 항염증 효과 등이 보고된 바, 식품첨가물로서의 이용가치도 높다.The extract used in the present invention has been widely used in traditional Korean medicine as a herbal medicine as a medicinal herb with turmeric and contains curcumin, which is a main ingredient of food flavoring agents in Southeast Asia, and its antioxidant and anti-inflammatory effects have been reported. Its use value is also high.
본 발명에서 사용된 중국부추는 백합과의 다년초로 서식지는 한국, 중국, 일본 등이며, 그 중에서도 특히 한국과 중국에서 주로 서식하고 식용 및 약용, 특히 이질을 치료하는 지사제 또는 지혈제로 사용되고 있다. 가식부로 이용되는 부분은 줄기와 잎이며, 주로 생채소 형태로 많이 식용되어 왔다.Chinese leek used in the present invention is a perennial herb of the family Liliaceae, and its habitat is Korea, China, Japan, etc. Among them, it is inhabited mainly in Korea and China, and is used as a branch or hemostatic agent for treating edible and medicinal, especially dysentery. The parts used as edible parts are stems and leaves, and they have been mainly eaten in the form of raw vegetables.
본 발명에서 사용된 고사리는 고사리과의 다년생 양치류로 서식지는 우리나라 전국 각지와 일본 오키나와, 중국 사할린, 시베리아, 유럽, 남·북 아메리카이며, 전분 원료, 해열, 이뇨, 설사, 황달 치료제 및 의용약으로 사용되고 있다. 가식부로 이용되는 부분은 어린순, 뿌리, 땅속줄기이다.The fern used in the present invention is a perennial fern of the fern family, and the habitat is all over Korea, Japan, Okinawa, China, Sakhalin, Siberia, Europe, South and North America, and used as starch raw material, antipyretic, diuretic, diarrhea, jaundice treatment and medicinal medicine. have. The parts used as edible parts are young shoots, roots and underground stems.
본 발명에 따르면 봉출을 수회에 걸쳐 추출 용매로 1 ∼ 8 시간 동안 추출하여 1차 추출물을 얻고, 이를 다시 알코올로 추출하여 침전물 분획인, 대식세포 활성화능을 갖는 추출물을 제조하는 바, 상기 추출물을 제조하는 방법을 보다 상세히 설명하면 다음과 같다.According to the present invention, the extract is extracted several times with an extraction solvent for 1 to 8 hours to obtain a primary extract, which is then extracted with alcohol to prepare an extract having a macrophage activation ability, which is a precipitate fraction. Hereinafter, the manufacturing method will be described in detail.
이때, 봉출 이외에 중국부추나 고사리도 같거나 유사한 방식으로 추출할 수 있다.At this time, the Chinese leek or fern in addition to the extraction can be extracted in the same or similar manner.
먼저, 예컨데 봉출로 대표되는 식용식물을 고온에서 끓여, 효소 활성을 제거하고 균질제로 분쇄함으로써, 추출이 단시간동안 효과적으로 이루어지도록 한다.First, for example, by edible plant is represented by the boil at high temperature to remove the enzyme activity and pulverized with a homogeneous agent, so that the extraction is effectively made for a short time.
분쇄된 시료를 추출 용매에 넣고, 1 ∼ 8 시간 동안 교반하면서 추출하여 1차 추출물을 얻는 바, 추출 시간이 상기 범위를 벗어나면 대식세포 활성화도가 감소하는 문제점이 있다. 상기 추출 용매로는 산이나 약염기, 에탄올, 증류수 중에서 선택된 하나 또는 2 이상의 혼합 추출용매를 사용하는 것이 바람직하며, 특히 증류수를 사용하는 것이 더욱 바람직하다.The pulverized sample is put into an extraction solvent and extracted with stirring for 1 to 8 hours to obtain a primary extract. If the extraction time is out of the above range, there is a problem that the macrophage activation is reduced. As the extraction solvent, it is preferable to use one or two or more mixed extraction solvents selected from acid, weak base, ethanol and distilled water, and more preferably distilled water.
상기 추출과정에서 봉출 및 고사리는 70 ∼ 100 ℃ 온도에서 추출하는 것이 바람직한 바, 상기 범위 밖의 온도에서 추출할 경우, 대식세포 활성화도가 감소하는 문제점이 있다.Extraction and fern in the extraction process is preferably extracted at a temperature of 70 ~ 100 ℃ bar, when extracted at a temperature outside the above range, there is a problem that the macrophage activation is reduced.
상기 추출과정에서 중국부추는 4 ℃ ∼ 상온(25 ℃)에서 추출하는 것이 바람직한 바, 상기 범위 밖의 온도, 즉, 상온 이상의 고온에서 추출할 경우, 대식세포 활성화도가 오히려 감소하는 문제점이 있다.In the extraction process, Chinese leek is preferably extracted at 4 ° C. to room temperature (25 ° C.), and when extracted at a temperature outside the above range, that is, at room temperature or higher, macrophage activation is rather reduced.
이와 같이 제조된 식용식물의 1차 추출물을 동결건조하고, 이 획분을 메탄올로 환류추출한다. 메탄올 환류추출물 중 비가용 성분을 감압농축하고, 다시 감압농축된 추출물 수용액을 에탄올로 추출하여 비가용 성분을 분리함으로써, 봉출, 중국부추 및 고사리 중에서 선택된 식용식물의 최종 추출물을 얻는다.The primary extract of the edible plant thus prepared is lyophilized and the fraction is refluxed with methanol. The methanol extract is concentrated under reduced pressure, and the extract is concentrated under reduced pressure, and the extract aqueous solution is extracted with ethanol to separate the insoluble component, thereby obtaining a final extract of the edible plant selected from the extract, Chinese leek and fern.
이렇게 얻어진 본 발명에 따른 봉출을 주재로 하는 식용식물 추출물은 대식세포 활성화도를 측정한 결과 종래의 대식세포 활성화제보다 활성화능이 우수한 바, 대식세포 활성화제로 유용하게 사용될 수 있다.Thus obtained edible plant extract based on the present invention according to the measurement of macrophage activation degree is superior to the conventional macrophage activator bar as a result, can be usefully used as a macrophage activator.
또한, 본 발명에 따르면 상기 봉출 추출물에 추가로 중국부추 추출물 또는 고사리 추출물을 단독으로 또는 혼합하여 첨가하여 대식세포 활성화능을 갖는 식용식물 추출물로 유용하게 사용할 수 있다.In addition, according to the present invention can be usefully used as an edible plant extract having a macrophage activation ability by adding to or in addition to the Chinese leek extract or fern extract in addition to the extract.
본 발명의 식용식물 추출물은 당 30 ∼ 60 중량%, 단백질 5 ∼ 40 중량%, 산성당 2 ∼ 20 중량%, 기타 조성물 5 ∼ 35 중량%를 함유하는 특성을 갖는다.The edible plant extract of the present invention has the property of containing 30 to 60% by weight of sugar, 5 to 40% by weight of protein, 2 to 20% by weight of acidic sugar, and 5 to 35% by weight of other compositions.
본 발명에서는 당과 단백질 각각의 실활 실험을 통해, 대식세포 활성의 본체가 당이라는 것을 확인할 수 있으며, 따라서 본 발명의 식용식물 추출물을 구성하는 구성성분인 당과 단백질의 비율보다는 활성 본체인 당의 존재 여부가 대식세포 활성화에 결정적인 역할을 한다는 것을 확인할 수 있다.In the present invention, the deactivation experiment of sugar and protein, respectively, it can be confirmed that the main body of macrophage activity is a sugar, and therefore the presence of the active body sugar rather than the ratio of the sugar and protein constituting the edible plant extract of the present invention Whether or not it plays a decisive role in macrophage activation.
또한, 본 발명의 식용식물 추출물이 포함하는 당은 만노스 0.5 ∼ 10 몰%,갈락토스 3 ∼ 30 몰%, 글루코스 5 ∼ 80 몰%, 람노스 1 ∼ 20 몰%, 아라비노스 3 ∼ 20 몰% 및 자일로스 1 ∼ 20 몰%를 함유한다.In addition, the sugar contained in the edible plant extract of the present invention is 0.5 to 10 mol% of mannose, 3 to 30 mol% of galactose, 5 to 80 mol% of glucose, 1 to 20 mol% of rhamnose, 3 to 20 mol% of arabinose, and It contains 1-20 mol% of xylose.
본 발명에 따른 상기 추출방법을 통해서 얻어진 봉출 추출물은 이온교환 크로마토그래피, 소수 상호작용 크로마토그래피 및 겔 여과 크로마토그래피를 실시하여 대식세포 활성화도가 우수한 순수 물질로 분리된다.The extract obtained through the extraction method according to the present invention is separated into a pure substance having excellent macrophage activation by performing ion exchange chromatography, hydrophobic interaction chromatography and gel filtration chromatography.
본 발명에 따른 봉출을 주재로 하는 식용식물 추출물 또는 정제분을 유효성분으로 함유하는 대식세포 활성화제는 식품으로 섭취, 사용될 수 있으나, 의약 형태로 투여될 수도 있는 바, 의약으로 사용되는 경우, 적절한 방법, 예를 들면 경구 또는 비경구의 방법으로 투여될 수 있다.Macrophage activator containing an edible plant extract or purified powder based on the extract according to the present invention as an active ingredient can be consumed and used as food, but may be administered in a medicinal form, when used as a medicament, Or by parenteral or parenteral methods.
대식세포 활성화제의 투여량은 평균 몸무게가 70 kg인 성인환자를 기준으로 할 때 일반적으로 0.1 ∼ 400 mg/일이다. 따라서, 일반 성인환자의 경우 약제학적으로 허용 가능한 부형제 또는 담체를 사용하여 유효 추출물이 0.05 ∼ 200 mg 함유되도록 정제 또는 캡슐로 제형화하여 하루에 한번 또는 여러번에 걸쳐서, 1회의 투여량 또는 여러번의 투여량으로 복용된다. 상기한 투여량은 평균적인 경우를 예시한 것으로써 개인적인 차이에 따라 그 투여량이 높거나 낮을 수 있다.The dosage of macrophage activators is generally 0.1-400 mg / day based on adult patients having an average weight of 70 kg. Thus, in general adult patients, one dose or several administrations, once or several times a day, may be formulated into tablets or capsules containing pharmaceutically acceptable excipients or carriers to contain 0.05-200 mg of the effective extract. It is taken in dose. The above dosages are illustrative of the average case and may be higher or lower depending on individual differences.
사람에게 적용함에 있어서, 본 발명의 추출물은 단독으로 투여될 수 있으나, 일반적인 투여방식과 표준 약제학적 관행(standard pharmaceutical practice)을 고려하여 선택된 약제학적 담체와 혼합되어 투여될 수 있다.In human application, the extract of the present invention may be administered alone, but may be administered in admixture with a pharmaceutical carrier selected in consideration of general mode of administration and standard pharmaceutical practice.
이때 담체로는 글리세린, 땅콩유, 폴리비닐피롤리돈, 올리브유, 에탄올, 벤질알콜, 프로필렌글리콜, 물 등의 액체담체와 락토스, 카올린, 슈크로스, 결정성셀룰로스, 옥수수 전분, 탈크, 펙틴, 아가, 스테아르산, 마그네슘 스테아레이트, 레시틴, 염화나트륨 등의 고체담체를 사용할 수 있다.At this time, the carrier is glycerin, peanut oil, polyvinylpyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water and other liquid carriers, lactose, kaolin, sucrose, crystalline cellulose, corn starch, talc, pectin, agar. Solid carriers such as stearic acid, magnesium stearate, lecithin, sodium chloride and the like can be used.
또한, 본 발명의 대식세포 활성화제는 식품 또는 의약용으로 사용되는 경우, 다양한 형태로 제조될 수 있는 바, 예를 들면 액체담체를 사용할 경우, 유액, 시럽, 연질 젤라틴 캡슐, 겔 등으로 약제화할 수 있으며 고체담체를 사용할 경우, 정제, 캡슐, 분말, 과립제 등으로 제조할 수 있다.In addition, the macrophage activator of the present invention can be prepared in a variety of forms when used for food or medicament, for example, when using a liquid carrier, it is formulated with emulsion, syrup, soft gelatin capsules, gels, etc. When using a solid carrier, it can be prepared as tablets, capsules, powders, granules and the like.
이하 본 발명을 실시예에 의거하여 더욱 상세히 설명하겠는 바, 본 발명이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited by Examples.
실시예 1 ∼ 3: 계통 추출에 의한 식용식물의 추출물 제조Examples 1 to 3: Preparation of edible plant extracts by lineage extraction
봉출, 중국부추 및 고사리 등, 3종의 식용식물을 각각 도 1의 방법에 따라 계통 추출하였다.Three kinds of edible plants, such as bonsai, Chinese leek, and fern, were systematically extracted according to the method of FIG. 1.
먼저 식용식물을 100 ℃에서 5 분간 끓여서 효소 활성을 제거하고, 7,000 rpm에서 20 분간 균질제(homogenizer)로 분쇄한다. 분쇄된 시료를 5,000 rpm에서 30 분간 원심분리하고, 여기서 얻은 상등액을 동결건조하여 분획 1을 제조하였다.First, edible plants are boiled at 100 ° C. for 5 minutes to remove enzymatic activity, and pulverized with a homogenizer for 20 minutes at 7,000 rpm. The ground sample was centrifuged at 5,000 rpm for 30 minutes, and the supernatant obtained here was lyophilized to prepare Fraction 1.
상기 과정에서 침전물은 동결건조 후 연속적으로 헥산으로 2 시간 동안 추출한 다음, 이 추출액을 원심분리하여 상등액을 농축, 동결건조함으로써, 분획 2를 얻었다.In the above process, the precipitate was continuously extracted with hexane for 2 hours after lyophilization, and then the extract was centrifuged to concentrate and lyophilize the supernatant, thereby obtaining fraction 2.
여기서 나온 침전물을 상기와 같은 방법으로 아세톤, 메탄올, 증류수의 순으로 2 시간 동안 추출하고 원심분리하여, 각각의 상등액을 농축, 동결건조함으로써, 분획 3, 4, 5를 얻었다.The precipitate obtained here was extracted for 2 hours in the order of acetone, methanol and distilled water in the same manner as described above and centrifuged to obtain fractions 3, 4 and 5 by concentrating and lyophilizing each supernatant.
비교예 1 ∼ 22Comparative Examples 1 to 22
표 2에 제시한 바와 같이, 시중에서 구입한 각종 식용식물을 실시예 1 ∼ 3과 같은 방법으로 계통 추출하였다.As shown in Table 2, various edible plants purchased commercially were systematically extracted in the same manner as in Examples 1-3.
실험예 1 : 대식세포 활성화도 측정Experimental Example 1 Measurement of Macrophage Activation
상기와 같은 방법에 의하여 계통 추출된 실시예 1 ∼ 3, 비교예 1 ∼ 22의 식용식물 추출물의 분획 1 ∼ 5 중에서 활성 측정이 가능한 분획 1, 4, 5에 대한 대식세포 활성화도를 측정하였다.Macrophage activation of the fractions 1, 4, and 5, which can measure the activity, was measured in fractions 1 to 5 of the edible plant extracts of lineage-extracted Examples 1 to 3 and Comparative Examples 1 to 22 by the same method.
먼저 계통추출에 의하여 조제된 각각의 분획을 생리식염수에 용해시켜 100 ㎍/ml의 추출물 용액을 만들었다.First, each fraction prepared by phylogenetic extraction was dissolved in physiological saline to make an extract solution of 100 ㎍ / ml.
5 ∼ 8 주령 웅성 ICR 마우스의 복강 내에 1 ml의 티오글리콜레이트(thioglycollate) 배지를 주입한 뒤 48 ∼ 72 시간 내에 헤페스(Hepes), 페니실린(Penicillin)/스트렙토마이신(Streptomycin), 암포테리신 B(Amphotericin B)를 함유한 RPMI-1640 배지로 세척하고 대식세포를 마우스의 복강내에서 회수하였다. 회수된 대식세포를 RPMI-1640 배지로 두 번 세척하고 세포수가 1×106개/ml가 되도록 RPMI-1640 배지에 재분산시켰다. 이 분산액을 96-우물 플레이트(well plate)의 각 우물에 180 ㎕씩 분주한 후 37 ℃, 5 %, 이산화탄소에서 2 시간 동안 배양하였다. 대식세포가 각 우물에 단층을 형성하면 비부착세포를 RPMI-1640 배지로 두 번 세척하여 제거한 다음, 10 % 우태아혈청(fetal bovine serum)을 함유한 RPMI-1640 배지를 각 우물에 180 ㎕씩 분주하고 여기에 상기에서 제조한 추출물 용액 20 ㎕를 각각 가하여 37 ℃, 5 %, 이산화탄소에서 24 시간 배양하여 대식세포를 활성화시킨다. 이렇게 활성화된 대식세포의 단층에 0.1 % 트리톤(triton) X-100(25 ㎕)을 가하여 대식세포의 세포막을 용해시켜 이 때 분비되는 리소좀(lysosome)의 인산가수분해효소의 기질로써 10 mM, ρ-니트로페닐 인산염(150 ㎕)을 0.1 M 시트르산염 완충액(50 ㎕)과 같이 넣어주어 1 시간 동안 산성 상태에서 반응시키고 0.2 M 붕산염 완충액을 가하여 반응을 정지시킨 후 자외선 분광광도기(ELISA reader, Bio-Rad 3550-UV)로 405 ㎚에서 흡광도를 측정하였다.Hepes, Penicillin / Streptomycin, and amphotericin B within 48 to 72 hours after injecting 1 ml of thioglycollate medium into the abdominal cavity of 5-8 week old male ICR mice. Washed with RPMI-1640 medium containing (Amphotericin B) and macrophages were harvested intraperitoneally of mice. The recovered macrophages were washed twice with RPMI-1640 medium and redispersed in RPMI-1640 medium so that the cell number was 1 × 10 6 cells / ml. This dispersion was dispensed into each well of a 96-well plate (180 μl) and incubated for 2 hours at 37 ℃, 5%, carbon dioxide. When macrophages form a monolayer in each well, non-adherent cells are washed twice with RPMI-1640 medium and removed, followed by 180 μl of RPMI-1640 medium containing 10% fetal bovine serum in each well. Dispense and add 20 μl of the extract solution prepared above, and incubate for 24 hours at 37 ° C., 5%, and carbon dioxide to activate macrophages. 0.1 mM Triton X-100 (25 μl) was added to the monolayer of activated macrophages to dissolve the cell membranes of macrophages. As a substrate of lysosome phosphatase, 10 mM, ρ Nitrophenyl phosphate (150 μl) was added together with 0.1 M citrate buffer (50 μl) to react in acidic condition for 1 hour, and the reaction was stopped by addition of 0.2 M borate buffer solution followed by ultraviolet spectrophotometer (ELISA reader, Bio). Absorbance at 405 nm with -Rad 3550-UV).
이와 같은 방법으로 검색한 각 추출용액별 흡광도를, 음성대조군인 생리식염수의 흡광도를 기준으로 비교하여, 이 값을 대식세포 활성화도로 나타내었다.The absorbance of each extraction solution retrieved in this manner was compared with the absorbance of physiological saline, a negative control group, and this value was expressed as a macrophage activation diagram.
실시예 1 ∼ 3의 대식세포 활성화도를 1차 검색한 결과를 표 1에 나타내었다. 또한, 비교예 1 ∼ 22의 대식세포 활성화도를 1차 검색한 결과를 표 2에 나타내었다.Table 1 shows the results of the first search for the degree of macrophage activation of Examples 1-3. In addition, the results of the first search for the macrophage activation level of Comparative Examples 1 to 22 are shown in Table 2.
상기 표 1 ∼ 2에서 확인할 수 있는 바와 같이, 1차 검색 결과 봉출의 열수 추출물이 가장 우수하고, 그 외에 중국부추의 냉수 추출물, 고사리의 열수 추출물의 대식세포 활성화도가 다른 비교예 1 ∼ 22의 식물에 비해 높게 나타났다.As can be seen in Tables 1 and 2 above, the primary search results show that the hot water extract of the extract is the most excellent, and that the macrophage activation levels of the cold water extract of Chinese leek and the hot water extract of bracken are different. Higher than plants.
따라서, 봉출, 중국부추, 고사리에 대해서 다음 실험을 진행하였다.Therefore, the following experiment was carried out on the extract, Chinese leek, and fern.
실시예 4 ∼ 15, 비교예 23 ∼ 34 : 추출 조건Examples 4-15, Comparative Examples 23-34: Extraction conditions
봉출, 중국부추, 고사리에 대한 각각의 식용식물 추출물을 제조하는데 있어서, 대식세포 활성화도와 수율을 최대화할 수 있는 추출 조건을 찾고자 하였다. 추출용매, 추출온도 또는 추출시간을 다르게 하여 각 추출물을 제조하고, 각각의 조건에 따른 대식세포 활성화도와 수율을 검토하였다.In preparing each edible plant extract for extract, Chinese leek and fern, we tried to find the extraction conditions to maximize macrophage activation and yield. Each extract was prepared by different extraction solvent, extraction temperature or extraction time, and the macrophage activation and yield according to each condition were examined.
추출용매는 증류수, 산, 메탄올, 아세톤을 사용하였으며, 추출 용액의 농도를 100 ㎍/ml로 만들었다. 추출온도는 4 ℃에서부터 100 ℃까지 변화시켰고, 추출시간은 2 시간에서부터 24 시간까지 변화시켜, 추출조건에 변화에 따른 대식세포 활성화도와 수율을 측정하였다.Distilled water, acid, methanol, acetone was used as the extraction solvent, and the concentration of the extraction solution was made to 100 ㎍ / ml. Extraction temperature was changed from 4 ℃ to 100 ℃, extraction time was changed from 2 hours to 24 hours, and the macrophage activation and yield according to the extraction conditions were measured.
상기 실험 결과로써, 봉출의 대식세포 활성화도와 수율을 표 3에, 중국부추의 대식세포 활성화도와 수율을 표 4에, 고사리의 대식세포 활성화도와 수율을 표 5에 각각 제시하였다.As a result of the experiment, the macrophage activation and yield of the extract in Table 3, the macrophage activation and yield of Chinese leek in Table 4, the macrophage activation and yield of ferns are shown in Table 5.
상기 표 3 ∼ 5에서 확인할 수 있는 바와 같이, 봉출, 중국부추, 고사리를 추출 용매를 다르게 하여 추출한 추출물의 대식세포 활성을 검색한 결과, 대체적으로 메탄올, 아세톤 등의 유기용매에서는 비교적 낮은 활성을 보였으며 수율도 낮은 반면, 증류수 추출물은 높은 활성과 높은 수율을 나타내었다.As can be seen in Tables 3 to 5, the macrophage activity of the extract extracted from the extract, Chinese leek, and fern with different extraction solvents showed relatively low activity in organic solvents such as methanol and acetone. While the yield was low, the distilled water extract showed high activity and high yield.
또한, 봉출과 고사리의 경우는 저온 추출물보다 고온 열수 추출물이 대식세포 활성화능이 우수하였으며, 중국부추의 경우는 고온 추출물보다 저온 냉수 추출물이 대식세포 활성화능이 우수하였다.In addition, hot water extracts were better in macrophage activation than cold extracts in the case of extracts and ferns, and cold water extracts were better in macrophage activation than hot extracts in Chinese leek.
한편, 추출 시간을 3 시간으로 할 때 대식세포 활성화도와 수율이 최대값을 나타냈으며, 10 시간 이상에서는 대식세포 활성화능과 수율이 급격히 감소하는 결과를 나타내었다.On the other hand, when the extraction time was 3 hours, the macrophage activation and yield showed the maximum value, and after 10 hours, the macrophage activation capacity and yield showed a sharp decrease.
실시예 16 : 알코올 추출Example 16: Alcohol Extraction
분쇄된 봉출 500 g을 100 ℃의 열수로 3 시간 동안 추출하였다. 이와 같은 과정을 3회 반복 추출하여 추출물을 모아 동결건조하였다. 4회 추출물은 수율과 상대활성이 급격히 감소하였기 때문에, 1 ∼ 3회 추출물만을 모아 추출물을 제조하였다.500 g of ground milled extract was extracted with hot water at 100 ° C. for 3 hours. This process was repeated three times to extract the extracts were lyophilized. Since the fourth extract was rapidly reduced in yield and relative activity, the extract was prepared by collecting only 1-3 extracts.
그런 다음, 이 추출액을 메탄올로 5회 환류추출하여 메탄올 가용 성분을 분리하였다. 메탄올 비가용 성분인 침전물은 감압농축한 후 적당량의 증류수에 녹여 에탄올로 추출하여 에탄올 가용 성분과 에탄올 비가용 성분을 얻었다.Then, the extract was refluxed five times with methanol to separate methanol soluble components. The precipitate, a methanol insoluble component, was concentrated under reduced pressure, dissolved in an appropriate amount of distilled water, and extracted with ethanol to obtain an ethanol-soluble component and an ethanol-insoluble component.
각 획분의 대식세포 활성화 효과를 측정한 결과 메탄올 가용성분은 130 %의 낮은 활성을 나타낸 반면, 에탄올 가용 획분은 225 %의 높은 활성을 나타내었고 에탄올 침전 분획은 270 %의 가장 높은 활성을 나타내었다. 따라서, 에탄올 침전 분획에 대한 이후 실험을 진행하는 바, 본 발명에서 식용식물 추출물이라 함은 상기 에탄올 침전 분획을 말한다.As a result of measuring the macrophage activation effect of each fraction, methanol soluble fraction showed low activity of 130%, ethanol soluble fraction showed high activity of 225% and ethanol precipitation fraction showed the highest activity of 270%. Therefore, the following experiment on the ethanol precipitation fraction, the edible plant extract in the present invention refers to the ethanol precipitation fraction.
중국 부추는 상기 봉출의 추출방법에 따르되, 25 ℃에서 증류수로 추출하여 1차 추출물을 제조하였다. 중국 부추 추출물은 대식세포 활성화도가 223 %로 1차 추출물에 비해 약간 상승한 대식세포 활성을 보였다.Chinese leek according to the extraction method of the above-mentioned extract, was extracted with distilled water at 25 ℃ to prepare a primary extract. Chinese leek extract showed a macrophage activity of 223%, slightly higher than that of the primary extract.
고사리에 대해서도 상기 봉출의 추출방법에 따라 추출물을 얻었다. 고사리 추출물은 대식세포 활성화도가 235 %로 나타났다. 고사리의 메탄올 또는 에탄올 가용성분인, 저분자 물질은 활성이 나타나지 않는 것으로 보아 지금까지 보고된 면역 활성 물질의 대부분이 저분자 획분보다 고분자 획분의 다당이라는 사실과일치하는 것으로 보였다.Also about the fern extract was obtained according to the extraction method of the above-mentioned. Fern extract showed 235% macrophage activation. The low molecular weight, fern methanol or ethanol soluble components, did not appear to be active, which seemed to coincide with the fact that most of the immunoactive substances reported so far were polysaccharides of polymer fractions rather than low molecular fractions.
실험예 2 : 추출물의 조성Experimental Example 2 Composition of the Extract
봉출, 중국부추, 고사리 등 각 식용식물 추출물에 대해 화학적 조성을 발색반응에 의한 스펙트로포토미터로 검색하였다.The chemical composition of each edible plant extract, such as extract, Chinese leek and fern, was searched by spectrophotometer by color reaction.
봉출, 중국부추, 고사리 등의 각 식용식물에 대한 추출물, 각각의 화학적 조성을 표 6에 제시하였다.Extracts for each edible plant, such as extract, Chinese leek, fern, and the respective chemical compositions are shown in Table 6.
실험예 3 : 당의 조성Experimental Example 3 Composition of Sugar
상기 실험예 2에서 사용한 각각의 추출물의 당을 기체 크로마토그래피와 얇은막 크로마토그래피를 이용하여 구성당 분석을 실시하였다.The sugar of each extract used in Experimental Example 2 was analyzed per component using gas chromatography and thin layer chromatography.
각각의 추출물의 구성당 분석 결과를 표 7에 제시하였다.The analysis results per component of each extract are shown in Table 7.
실험예 4 : 대식세포 활성화 본체의 검토Experimental Example 4 Examination of the Body of Macrophage Activation
봉출 추출물, 중국부추 추출물 및 고사리 추출물은 당과 단백질이 주성분이므로, 대식세포 활성화 물질 본체를 파악하기 위하여 당 또는 단백질을 각각 실활시켜 대식세포 활성을 검토하였다.Since extracts, Chinese leek extracts, and fern extracts are mainly composed of sugars and proteins, the macrophage activity was examined by deactivating sugars or proteins, respectively, to identify macrophage activator substances.
각각의 식용식물 추출물을 프로나제(pronase) 처리에 의하여 단백질을 분해하여 선택적으로 실활시킨 다음 대식세포 활성화도를 검토하였다. 또한, 과요오드산염을 이용하여 당 부위를 선택적으로 실활시켜 대식세포 활성화도를 검토하였다.Each edible plant extract was selectively inactivated by protein degradation by pronase treatment, and then examined for macrophage activation. In addition, the macrophage activation was examined by selectively inactivating the sugar site using a periodate.
상기 대식세포 활성 측정 결과를 표 8에 제시하였다.The macrophage activity measurement results are shown in Table 8.
표 8에서 확인할 수 있는 바와 같이, 단백질을 실활 시킨 경우는 대식세포 활성이 거의 같은 값을 보이거나, 약간의 감소를 보인 반면, 당을 실활시킨 경우는 대식세포 활성이 현격하게 감소하였다. 따라서 본 실험의 재료인 봉출, 중국부추, 고사리 각각의 추출물의 대식세포 활성 본체는 다당이며 단백질도 일부 관여하는 것으로 추정된다. 또한 당과 단백질의 구성 비율보다는 활성 본체인 당의 존재 여부가 대식세포 활성에 결정적인 영향을 미친다는 것을 알 수 있었다.As can be seen in Table 8, the protein inactivation showed almost the same value or a slight decrease in macrophage activity, whereas the inactivation of sugar significantly reduced the macrophage activity. Therefore, the macrophage active body of each extract of the extract, Chinese leek, and fern, which is the material of this experiment, is polysaccharide and it is assumed that some protein is involved. In addition, it was found that the presence of an active body sugar rather than the composition ratio of sugar and protein has a decisive effect on macrophage activity.
실시예 17 : 봉출 추출물의 분리 및 정제Example 17 Separation and Purification of the Extract
대량 추출시 분리된 획분 중 가장 대식세포 활성이 높았던 봉출 추출물을 음이온 교환수지인 DEAE-도요펄 650C 칼럼(Cl- 형태, 3.5 × 38 cm)을 이용하여 시료 성분의 이온 강도에 따라 용출시켰다. DW 용출 획분을 CZ-1-0, 0.1 M 염화나트륨 농도에서 용출된 CZ-1-Ⅰ, 0.2 M 염화나트륨 용액에서 용출된 CZ-1-Ⅱ, 0.3 M 염화나트륨 농도에서 용출된 CZ-1-Ⅲ, 0.4 M 염화나트륨 농도에서 용출된 CZ-1-Ⅳ,0.5 M 염화나트륨 농도에서 용출된 CZ-1-Ⅴ, 0.6 M 염화나트륨 농도에서 용출된 CZ-1-Ⅵ, 0.7 M 염화나트륨 농도에서 용출된 CZ-1-Ⅶ의 8개 획분으로 분리하여 각각의 대식세포의 활성화도를 측정하였다.The extracted extract, which had the highest macrophage activity among the fractions separated during mass extraction, was eluted according to the ionic strength of the sample components using an DEAE-Toyopearl 650C column (Cl-form, 3.5 × 38 cm), an anion exchange resin. DW elution fractions were CZ-1-0, CZ-1-I eluted at 0.1 M sodium chloride, CZ-1-II eluted in 0.2 M sodium chloride solution, CZ-1-III eluted at 0.3 M sodium chloride, 0.4 CZ-1-IV eluted at M sodium chloride, CZ-1-V eluted at 0.5 M sodium chloride, CZ-1-VI eluted at 0.6 M sodium chloride, CZ-1-Ⅶ eluted at 0.7 M sodium chloride The activity of each macrophage was measured by separating into 8 fractions of.
상기 방법에 따라, 분리한 8개의 획분에 대해 측정한 대식세포 활성화도와 수율을 표 9에 제시하였다.According to the method, the macrophage activation and yield measured for the eight fractions separated are shown in Table 9.
각 획분의 화학적 조성은 DW 용출 획분인 CZ-1-0이 당 61 %로 가장 높은 당함량을 보였지만 대식세포 활성화도는 매우 낮았고, 반면 대식세포 활성화도가 높았던 CZ-1-Ⅲ, CZ-1-Ⅳ 획분은 각각 당 14.7 %, 17 %, 단백질 30 %, 40.8 %로 염화나트륨 농도를 증가시킬수록 당 함량은 감소하고 단백질 함량은 증가하는 경향을보였다.The chemical composition of each fraction showed the highest sugar content of CZ-1-0, which is the DW eluting fraction (61% per sugar), but the macrophage activation was very low, whereas the macrophage activation was high in CZ-1-III and CZ-1. -IV fractions showed 14.7%, 17%, 30%, and 40.8% of sugar, respectively, and as the sodium chloride concentration increased, the sugar content decreased and the protein content increased.
실시예 18 : CZ-1-Ⅳ의 분획Example 18 Fraction of CZ-1-IV
DEAE-도요펄 650C에서 0.4 M 염화나트륨 비흡착 획분인 CZ-1-Ⅳ를 부틸-도요펄 650M에 의한 염화나트륨 역농도 구배에 따른 소수 상호작용 크로마토그래피를 행한 결과 2.0 M 염화나트륨에서 용출된 획분과 DW에서 용출된 획분으로 분리되었다. 이들 획분은 각각 유사한 활성을 나타내어 CZ-1-Ⅳ-A와 CZ-1-Ⅳ-B는 1.0 mg/mL의 농도에서 220 % 이상의 높은 활성을 보였으나 활성이 높은 CZ-1-Ⅳ-A를 주활성분으로 하여 정제하였다. 화학적 조성에서는 CZ-1-Ⅳ-A가 총당 함량이 71.7 %이고 단백질 함량은 16.7 %이며 CZ-1-Ⅳ-B는 총당 함량이 9.8 %이고 단백질 함량이 88.6 %를 나타내어 다당과 단백질 획분이 분리되었다.CZ-1-IV, a 0.4 M sodium chloride nonadsorbed fraction on DEAE-Toyopearl 650C, was subjected to hydrophobic interaction chromatography according to the sodium chloride reverse concentration gradient by butyl-Toyopearl 650M. Separated into eluted fractions. These fractions showed similar activity, respectively, indicating that CZ-1-IV-A and CZ-1-IV-B exhibited high activity of 220% or higher at 1.0 mg / mL, but showed high activity of CZ-1-IV-A. It refined as a main active ingredient. In chemical composition, CZ-1-IV-A contains 71.7% total sugar, 16.7% protein, and CZ-1-IV-B shows 9.8% total sugar and 88.6% protein. It became.
부틸-도요펄 650M에서 용출된 획분 중 활성과 다당성분이 높았던 CZ-1-Ⅳ-A를 분획 가능한 세파로제 CL-6B 칼럼(2 × 90 cm)을 선택하여 겔 여과 크로마토그래피를 실시하였다. 그 결과 CZ-1-Ⅳ-A1, CZ-1-Ⅳ-A2의 2개 획분으로 분리되었다. 용출부피에서 용출되었으므로 세파로제 CL-6B로 분획 가능한 분자량을 가진 물질인 CZ-1-Ⅳ-A1은 대식세포 활성을 측정한 결과 100 ㎍/mL 농도에서 250 % 이상의 높은 활성을 나타내었다. CZ-1-Ⅳ-A2는 낮은 대식세포 활성값을 나타내었다.Gel filtration chromatography was performed by selecting a Sepharose CL-6B column (2 × 90 cm) capable of fractionating CZ-1-IV-A, which had high activity and polysaccharide content in the fraction eluted from butyl-Toyopearl 650M. The result was separated into two fractions, CZ-1-IV-A1 and CZ-1-IV-A2. CZ-1-IV-A1, a substance having a molecular weight that can be fractionated with Sepharose CL-6B, was eluted in the elution volume and showed high activity of 250% or more at 100 ㎍ / mL. CZ-1-IV-A2 showed low macrophage activity.
CZ-1-Ⅳ-B도 또한 세파로제 CL-6B 칼럼(2 × 90 cm)을 선택하여 겔 여과 크로마토그래피를 실시한 결과 CZ-1-Ⅳ-B1, CZ-1-Ⅳ-B2, CZ-1-Ⅳ-B3의 3개 획분으로분리되었으며 이 중 CZ-1-Ⅳ-B2 획분이 100 ㎍/mL 농도에서 201 %의 비교적 높은 활성을 나타내었다.CZ-1-IV-B was also subjected to gel filtration chromatography using a Sepharose CL-6B column (2 × 90 cm), resulting in CZ-1-IV-B1, CZ-1-IV-B2, and CZ-1. Three fractions of -IV-B3 were isolated, of which CZ-1-IV-B2 fractions exhibited relatively high activity of 201% at a concentration of 100 µg / mL.
따라서 대식세포 활성물질의 분리, 정제 과정 중에 높은 대식세포 활성 성분을 가지며 화학적 조성이 다른 2개의 획분 CZ-1-Ⅳ-A1, CZ-1-Ⅳ-B2를 얻었다.Therefore, two fractions CZ-1-IV-A1 and CZ-1-IV-B2 having high macrophage active ingredients and different chemical compositions were obtained during the isolation and purification of macrophage active material.
실험예 5 : 생체 내에서의 단기 독성 실험Experimental Example 5: Short-term toxicity experiment in vivo
봉출 추출물의 급성 독성을 조사하였다. 경구투여에 의한 경우, 시료량 0 ~ 2,000 mg/kg의 모든 시험군에서 봉출 추출물은 독성을 나타내지 않았으며 LD50이 2,000 mg/kg 이상에 존재할 것으로 추정되었다.The acute toxicity of the extract was investigated. By oral administration, the extract extracts were not toxic in all test groups with a sample volume of 0 to 2,000 mg / kg and it was estimated that LD 50 was present at 2,000 mg / kg or more.
비경구투여에 의한 독성 실험에서는 시료량 0 ~ 1,000 mg/kg을 마우스의 꼬리에 정맥주사를 한 후 1주간 독성여부를 관찰한 결과 시료량 1,000 mg/kg의 투여군에서도 100 %의 생존율을 나타내어 본 시료가 독성을 나타내지 않음을 확인하였다.In the toxicity test by parenteral administration, the sample was injected intravenously into the tail of the mouse with a sample volume of 0 ~ 1,000 mg / kg, and the toxicity was observed for 1 week. It was confirmed that no toxicity was shown.
경구 투여에 의한 독성 실험 결과를 표 10에, 비경구 투여에 의한 독성 실험 결과를 표 11에 제시하였다.The results of toxicity experiments by oral administration are shown in Table 10, and the results of toxicity experiments by parenteral administration are shown in Table 11.
실시예 19 : 정제의 제조Example 19 Preparation of Tablets
봉출 추출물 2 mg2 mg extract extract
락토스 14 mgLactose 14 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
마그네슘 스테아레이트 1 mgMagnesium Stearate 1 mg
상기에서 나열한 성분들을 잘게 부숴 혼합한 다음, 직타법(direct tableting method)에 의해 정제를 제조하였다. 각 정제의 총량은 정제당 20 mg이 되도록 하였고, 그 중 봉출 추출물의 함량은 2 mg이었다.The ingredients listed above were finely mixed and then tablets were prepared by a direct tableting method. The total amount of each tablet was 20 mg per tablet, of which the extract content was 2 mg.
이와 같이, 본 발명에서는 먼저 식용식물을 계통 추출하여 대식세포 활성화능이 우수한 식용식물을 검색하였다. 검색결과 봉출 추출물이 대식세포 활성화능이 가장 우수하였고, 그 외에는 중국부추 및 고사리 추출물의 대식세포 활성화능이 우수하였으므로 이를 가지고 이후 실험을 진행하였다.As described above, in the present invention, the edible plant was first extracted to search for edible plants having excellent macrophage activation ability. As a result, the extracted extract had the best macrophage activation ability, and the Chinese leek and fern extract had the excellent macrophage activation ability.
봉출, 중국부추 및 고사리를 각각 용매 추출 및 알코올 추출하여 각각의 식용식물 추출물을 대량으로 얻었고, 이 식용식물 추출물들은 대식세포 활성화능이 매우 우수하여 대식세포 활성화제로 유용하게 사용할 수 있음을 확인하였다. 특히, 봉출 추출물로부터 대식세포 활성화능이 매우 우수한 순수 정제분을 분리하였다.Extracts of Chinese leek and fern, respectively, were extracted with solvent and alcohol, and each edible plant extract was obtained in large quantities. The edible plant extracts were found to be very useful as macrophage activators because of their excellent macrophage activation ability. In particular, pure purified powder having excellent macrophage activation ability was isolated from the extract.
상술한 바와 같이, 본 발명에 따라 봉출, 중국부추 및 고사리 중에서 선택된 식용식물, 특히 봉출을 추출하여 얻은 추출물은 대식세포 활성화능이 종래 대식세포 활성화제보다 현격히 우수하며, 특히 인체에 무해하고, 천연식물로부터 용이하게 분리 가능하므로 대식세포 활성화제로 매우 유용한 효과가 있다.As described above, the edible plant selected from the extract, Chinese leek and fern according to the present invention, particularly the extract obtained by extracting the macrophage activation ability is significantly superior to the conventional macrophage activator, especially harmless to the human body, natural plants Since it can be easily separated from the macrophage activator has a very useful effect.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990013398A KR100338521B1 (en) | 1999-04-15 | 1999-04-15 | Plant extract for eating activating macrophage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990013398A KR100338521B1 (en) | 1999-04-15 | 1999-04-15 | Plant extract for eating activating macrophage |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000066366A KR20000066366A (en) | 2000-11-15 |
KR100338521B1 true KR100338521B1 (en) | 2002-05-30 |
Family
ID=19580270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990013398A KR100338521B1 (en) | 1999-04-15 | 1999-04-15 | Plant extract for eating activating macrophage |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100338521B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100441641B1 (en) * | 2002-02-14 | 2004-07-23 | 학교법인 영광학원 | The physiological active materials from Acanthopanax sessiliflorus |
-
1999
- 1999-04-15 KR KR1019990013398A patent/KR100338521B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20000066366A (en) | 2000-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Extraction methods and activities of natural glucans | |
Mayell | Maitake extracts and their therapeutic potential-a review | |
Wachtel-Galor et al. | Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom | |
JP3020387B2 (en) | Antiviral substance | |
US6395311B2 (en) | Multicomponent biological vehicle | |
JP3768795B2 (en) | Xanthine oxidase inhibitor | |
CN101019893B (en) | Process of enriching effective antitumor part of periplaneta americana with polyamide | |
KR102143244B1 (en) | Composition for preventing, improving or treating arthritis comprising extract of Ganoderma lucidum, extract of Artemisia princeps or mixture thereof | |
US9005676B2 (en) | Pharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers | |
CN101032532B (en) | Medicine composition including active substrates extracted from Sang Huang, the preparing method and the application in the producing of medicine thereof | |
JP4451100B2 (en) | Immunostimulant and anticancer agent containing Tamogitake fruit body composition as active ingredient | |
KR100338521B1 (en) | Plant extract for eating activating macrophage | |
KR101790654B1 (en) | Extraction of polysaccharides from pine nut cake and composition comprising pine nut extract for preventing or treating liver cancer | |
KR20140120756A (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
KR100506950B1 (en) | Immune stimulative constituents of ginseng saponins | |
Mushroom et al. | Ganoderma lucidum | |
KR20210147247A (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR101796924B1 (en) | Composition for improving hepatic function containing ginseng berry extracts | |
Ovodov | Bioglycans and natural glycosides as a promising research topic in bioorganic chemistriy | |
KR100547554B1 (en) | A composition containing thawed bark, brownish, sumac extract having anti-inflammatory activity | |
KR20040085226A (en) | Composition comprising the extract or fraction isolated from Russian Mumie for activation of Immunity | |
KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
KR20180135845A (en) | Pharmaceutical compositions for preventing or treating cancers comprising the nanoparticles of Dendropanax morbifera | |
BERRY | THE CHEMICAL COMPOUNDS OF TURKEY BERRY (Solanum torvum Swartz) PLANTS THAT ARE EFFICACIOUS AS MEDICINE | |
KR20070014745A (en) | Exo-biopolymer isolated from submerged mycelial culture of grifola frondosa increasing immune activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090115 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |